-
Dizal Pharma’s Sunvozertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has unveiled the latest positive data for its next-generation epidermal growth factor receptor (EGFR) inhibitor sunvozertinib (DZD9008). The drug is in late-stage global studies for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (Exon20ins) mutation, both in the second-line stage following…
-
Hywin Holdings to Acquire Life Infinity for Health Management Expansion
•
China-based wealth management firm Hywin Holdings is set to move into the health management business through the acquisition of Beijing iLife3 Technology Co., Ltd (Life Infinity). The share transfer and capital increase agreement will require over RMB140 million (USD20.7 million) for Hywin to gain a controlling equity interest. The transaction…
-
HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint
•
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase III FRESCO-2 study for its VEGFR 1/2/3 inhibitor Elunate (fruquintinib) in advanced refractory metastatic colorectal cancer (CRC) has met the primary overall survival (OS) endpoint. The multi-center study, initiated in July 2020, recruited 691 patients…
-
Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar Global (HKG: 9960) to promote anti-infection diagnosis testing, with a particular focus on the HIV field. Financial details of the partnership were not disclosed. Partnership DetailsThe collaboration aims to increase access to Frontier’s long-acting HIV…
-
Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME
•
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed in a Phase I clinical study for its IBI324, a bispecific antibody (BsAb) targeting vascular endothelial growth factor A (VEGF-A) and angiopoietin2 (Ang-2) in diabetic macular edema (DME). Study DetailsThe Phase I dosage escalation study…
-
Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma
•
Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has received orphan drug designation (ODD) status from the US Food and Drug Administration (FDA) for its herpetic oncolytic virus MVR-C5252. The designation is for the drug’s use in treating malignant glioma. Drug DetailsMVR-C5252, developed in-house…
-
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
•
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as its executive vice president of global drug development and chief medical officer (CMO). Dr. Germa will report directly to CEO Dr. Qian Xueming. Role and ResponsibilitiesDr. Germa will lead the global development and translational research…
-
Ningbo Health Gene Raises Hundreds of Millions in Series C Financing
•
Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by SCGC. Other investors included BioTrack Capital, Hefeng Venture Capital, Yingong Venture Capital, and Binjiang Xincheng Development Investment. The proceeds will be directed…
-
Intuitive Surgical-Fosun JV Breaks Ground on Shanghai Medical Robot Base
•
Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture (JV) between China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and US firm Intuitive Surgical, Inc, has commenced construction on a 2.08-hectare headquarters and industrialization base. The medical robot manufacturing R & D center is situated in Zhangjiang Hi-Tech…
-
Bayer AG’s Q2 2022 Results Show Global Sales Growth Amid China VBP Pressures
•
Germany-based pharmaceutical giant Bayer AG (VIE: BAYN) released its Q2 2022 financial report, revealing a global sales growth of 9.6% year-on-year (YOY) in constant exchange rate terms to EUR12.8 billion (USD13 billion). The growth was driven by strong performances in the Pharmaceuticals and Consumer Health segments. Pharmaceuticals and Consumer HealthIn…
-
Intellective Biologics Raises Over RMB500m in Series C Financing Round
•
China-based macromolecule-focused Contract Development and Manufacturing Organization (CDMO) Intellective Biologics (Suzhou) Co., Ltd has reportedly raised over RMB500 million (USD74.1 million) in a Series C financing round. The round was co-led by Tsing Song Capital and Gaorong Capital, with participation from Fuho Capital, CNCB Investment, Founder Securities, and Win Harbor…
-
MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development
•
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of 130 million shares priced at RMB8.16 (USD1.21) per share on Shanghai’s Sci-Tech Innovation Board (STAR). With 655 million shares issued, the IPO will bring in RMB1.06 billion (USD157 million) for MicuRx. Product PipelineMicuRx’s MRX-I (contezolid),…
-
invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19
•
invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that its tender offer for all outstanding shares of UK bispecific antibody specialist F-star Therapeutics Inc. (Nasdaq: FSTX) has been extended. The existing offer of USD7.12 per share remains unchanged, representing a total deal value of…
-
Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China
•
US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of its non-nucleoside cytomegalovirus (CMV) inhibitor Prevymis (letermovir) in China. The drug received market approval in December 2021 for the prevention of CMV infection and CMV disease in adult recipients with CMV seropositive [R+] undergoing allogeneic…
-
BeiGene’s Q2 2022 Revenues Surge 120%, Brukinsa Sales Triple
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording USD304.5 million in product revenues, a 120% increase compared to USD138.6 million from the same period last year. The growth was primarily driven by strong sales of its Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib)…
-
Innovent Biologics and Sanofi Announce License Deal for Drug Development in China
•
China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have announced a license and collaboration agreement. Under the deal, Sanofi will license two of its drugs to Innovent for development in China, alongside Innovent’s PD-1 inhibitor Tyvyt (sintilimab). Sanofi will also invest EUR300 million (USD306…
-
Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge
•
US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a first quarterly dip in global revenues in two years. Global sales revenues were down 1% year-on-year (YOY) in constant currency terms to USD6.488 billion. This decline was primarily due to the full impact of generic…
-
Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip
•
Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year (YOY) increase in global sales to DKK83.3 billion (USD11.42 billion) in constant exchange rate terms. The company saw strong sales growth in International Operations, up 10% YOY, and in North America, up 24% YOY. Diabetes…
-
Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration
•
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a memorandum of understanding to collaborate with Hong Kong Science & Technology Park (HKSTP) and Shanghai Biomedicine Fund, a RMB 50 billion (USD 11.44 billion) municipal industry fund approved by the Shanghai government and initiated by…
-
Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and clinical observation for the Phase I clinical study of RAY1216, an innovative oral therapy for the novel coronavirus developed by its subsidiary Guangdong Raynovent Biotech Co., Ltd. The study results demonstrated good safety and pharmacokinetic…
